# Belite Bio, Inc: financial statements, quarterly

BLTE · Nasdaq · CIK 1889109 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/blte.md) · [Financials](/companies/blte/financials.md) · [Filings](/companies/blte/filings.md) · [Insiders](/companies/blte/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/blte/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2019-12-31) | period not labelled (2020-12-31) | period not labelled (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | [17.3](/filings/0001104659-23-040145.md) | [42.1](/filings/0001104659-24-033149.md) | [88.2](/filings/0001410578-25-000356.md) | [31.7](/filings/0001104659-26-037374.md) | [353](/filings/0001104659-26-037374.md) |
| Current assets | $m | not reported | not reported | [17.4](/filings/0001104659-23-040145.md) | [42.8](/filings/0001104659-24-033149.md) | [89.9](/filings/0001410578-25-000356.md) | [147](/filings/0001104659-26-037374.md) | [494](/filings/0001104659-26-037374.md) |
| Total assets | $m | not reported | not reported | [18.3](/filings/0001104659-23-040145.md) | [44.3](/filings/0001104659-24-033149.md) | [94.6](/filings/0001410578-25-000356.md) | [152](/filings/0001104659-26-037374.md) | [781](/filings/0001104659-26-037374.md) |
| Current liabilities | $m | not reported | not reported | [1.6](/filings/0001104659-23-040145.md) | [2.1](/filings/0001104659-24-033149.md) | [3.6](/filings/0001410578-25-000356.md) | [6.1](/filings/0001104659-26-037374.md) | [9.9](/filings/0001104659-26-037374.md) |
| Total liabilities | $m | not reported | not reported | [1.6](/filings/0001104659-23-040145.md) | [2.8](/filings/0001104659-24-033149.md) | [4.2](/filings/0001410578-25-000356.md) | [6.3](/filings/0001104659-26-037374.md) | [10.1](/filings/0001104659-26-037374.md) |
| Shareholders' equity | $m | [(3.7)](/filings/0001104659-23-040145.md) | [(7.0)](/filings/0001104659-24-033149.md) | [(15.1)](/filings/0001410578-25-000356.md) | [41.5](/filings/0001104659-26-037374.md) | [90.4](/filings/0001104659-26-037374.md) | [146](/filings/0001104659-26-037374.md) | [770](/filings/0001104659-26-037374.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

Shares outstanding: 39,339,960 at 2025-12-31, from the cover of the [20-F filed 2026-03-31](/filings/0001104659-26-037374.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.